awmsg logo



darunavir/cobicistat (Rezolsta®)


Reference No. 2193

Publication date:
02/09/2015


Appraisal information

darunavir/cobicistat (Rezolsta®) 800 mg/150 mg film-coated tablet


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: 10/06/2015
AWMSG meeting date: 15/07/2015
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 2115
Ministerial ratification: 27/08/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Darunavir/cobicistat (Rezolsta®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download